Identification and in silico structural insights of rare recurrent EGFR mutations as resistance mechanisms to osimertinib in EGFR-mutated lung cancer.

被引：0
|
作者：
Na Zhoutong
Wu, Changling
Lu, Binbin
Cao, Ran
Ma, Yutong
Bao, Hua
Ou, Qiuxiang
Wu, Xue
Shao, Yang
Wang, Zhaoxia
机构：
[1] Soochow Univ, Dept Med Oncol, Changzhou Canc Hosp, Changzhou, Peoples R China
[2] Nanjing Med Univ, Dept Med Oncol, Affiliated Hosp 2, Nanjing, Peoples R China
[3] Geneseeq Technol Inc, Translat Med Res Inst, Toronto, ON, Canada
[4] Nanjing Geneseeq Technol Inc, Nanjing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9531
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Acquired rare recurrent EGFR mutations as mechanisms of resistance to Osimertinib in lung cancer and in silico structural modelling
    Lin, Lin
    Lu, Qiang
    Cao, Ran
    Ou, Qiuxiang
    Ma, Yutong
    Bao, Hua
    Wu, Xue
    Shao, Yang
    Wang, Zhaoxia
    Shen, Bo
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (11): : 4005 - +
  • [2] Osimertinib in EGFR-Mutated Lung Cancer REPLY
    Herbst, Roy S.
    Wu, Yi-Long
    Tsuboi, Masahiro
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (07): : 675 - 676
  • [3] Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
    Alessandro Leonetti
    Sugandhi Sharma
    Roberta Minari
    Paola Perego
    Elisa Giovannetti
    Marcello Tiseo
    British Journal of Cancer, 2019, 121 : 725 - 737
  • [4] Resistance Mechanisms to Osimertinib Treatment in EGFR-Mutated Lung Cancer in a Real Life Cohort
    Steendam, C.
    Atmodimedjo, P.
    Paats, M.
    Van der Leest, C.
    Von der Thusen, J.
    Dinjens, W.
    Van Schaik, R.
    Dubbink, H.
    Aerts, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S562 - S562
  • [5] Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
    Leonetti, Alessandro
    Sharma, Sugandhi
    Minari, Roberta
    Perego, Paola
    Giovannetti, Elisa
    Tiseo, Marcello
    BRITISH JOURNAL OF CANCER, 2019, 121 (09) : 725 - 737
  • [6] Adjuvant therapy with Osimertinib in resectable EGFR-mutated lung cancer
    Gassa, Asmae
    Ozkan, Filiz
    Alakus, Hakan
    Bruns, Christiane
    ONKOLOGE, 2021, 27 (02): : 172 - 173
  • [7] Overcoming EGFR-TKI resistance in EGFR-mutated lung cancer
    Gardizi, M.
    Scheffler, M.
    Bos, M.
    Geist, T.
    Heukamp, L.
    Nogova, L.
    Toepelt, K.
    Fernandez-Cuesta, L.
    Culmann, H.
    Kaminsky, B.
    Panse, J.
    Becker, C.
    Mattonet, C.
    Serke, M.
    Schmitz, S.
    Schnell, R.
    Galetke, W.
    Hekmat, K.
    Buettner, R.
    Wolf, J.
    ONKOLOGIE, 2013, 36 : 30 - 30
  • [8] Adjuvant Osimertinib Improves Overall Survival in EGFR-Mutated Lung Cancer
    Kim, Edward S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (07) : 370 - 370
  • [9] Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-Mutated Non-small Cell Lung Cancer
    Lee, Jiyun
    Shim, Joon Ho
    Park, Woong-Yang
    Kim, Hee Kyung
    Sun, Jong-Mu
    Lee, Se-Noon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    CANCER RESEARCH AND TREATMENT, 2019, 51 (01): : 408 - 412
  • [10] Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT).
    Breadner, Daniel Adam
    Vincent, Mark David
    Liu, Geoffrey
    Rothenstein, Jeffrey
    Menjak, Ines B.
    Cheema, Parneet Kaur
    Juergens, Rosalyn A.
    Mithoowani, Hamid
    Bains, Puneet
    Wang, Ying
    Wheatley-Price, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345